AzTrials
AzTrials

Relapsed and Refractory B-cell Non-Hodgkin's LymphomaPhase 1/2NCT04697940

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

A Phase 1/2 study testing Decitabine-primed Tandem CAR19/20 engineered T cells, Fludarabine and Cyclophosphamide in people with Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma and Decitabine-primed Tandem CD19/CD20 CAR T Cells, run by Han weidong at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is an open-label, phase 1/2 study has the primary objective of decitabine-primed tandem CART 19/20 in patients with B-NHL who were confirmed as r/r B cell Non-Hodgkin's Lymphoma. A total of 19 to 33 patients are planned to be enrolled and receive decitabine-primed tandem CART 19/20 cell infusion. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Decitabine-primed Tandem CAR19/20 engineered T cells, Fludarabine and Cyclophosphamide
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
33 participants
Where
1 siteChina
Study dates
15 Apr 2021to 1 Sep 2026
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients eligible for inclusion in this study had to meet all of the following criteria:
  • Age ≥18 and ≤75 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 2.
  • Patients with histologically confirmed CD20+ and/or CD19+ B-cell NHL, including the following types defined by the World Health Organization (WHO) 2016:
  • Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), including Activated B-cell type (ABC) / Germinal center B-cell Type (GCB);
  • Primary mediastinal (thymic) large B-cell lymphoma (PMBCL);
Show all 35Show fewer
  • Transformed follicular lymphoma (TFL);
  • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBCL);
  • Follicular lymphoma (FL);
  • Mantle cell lymphoma (MCL) [pathologically confirmed, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1];
  • Marginal zone lymphoma (MZL), including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma.
  • Relapse after treatment with ≥2 lines systemic therapy for all the above disease types, or refractory disease for aggressive types (DLBCL-NOS, PMBCL, TFL and HGBCL). Relapse disease is defined as disease progression after last regimen. Refractory disease is defined as no CR to first-line therapy:
  • PD as best response to first-line therapy, or
  • SD as best response after at least 4 cycles of first-line therapy (eg, 4 cycles of R-CHOP), or
  • PR as best response after at least 6 cycles and biopsy-proven residual disease or disease progression ≤ 6 months of therapy, or
  • Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or relapsed less than or equal to 12 months of ASCT (must have biopsy proven recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy.
  • Individuals must have received adequate prior therapy:
  • For MCL, prior therapy must have included:
  • Anthracycline or bendamustine-containing chemotherapy and
  • Anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and
  • Bruton's tyrosine kinase inhibitor (BTKi)
  • For other types, prior therapy must have included:
  • Anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and
  • Anthracycline containing chemotherapy regimen.
  • For individual with transformed FL must have relapse or refractory disease after transformation to DLBCL.
  • Successful leukapheresis assessment and preculture of T cells.
  • Life expectancy > 3 months.
  • According to Lugano response criteria 2014, there should be at least one evaluable tumor focus. Evaluable tumor focus was defined as that with the longest diameter of intranodal focus > 1.5cm, the longest diameter of extranodal focus > 1.0cm assessed by computed tomography (CT) or magnetic resonance imaging (MRI).
  • Subjects must be willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide formalin-fixed paraffin-embedded (FFPE) tumor tissue block or freshly cut unstained slides.
  • Functions of important organs meet the following requirements: Echocardiography showed left ventricular ejection fraction ≥50%. Serum creatinine ≤1.5 × upper limit of normal range (ULN) or endogenous creatinine clearance ≥45mL/min (cockcroft-gault formula); Alanine ULN, Total bilirubin ≤1.5× ULN; Pulmonary function: ≤CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) ≥91% in indoor air environment.
  • Blood routine (normal values shall not be obtained with growth factors, and hemocytopenia caused by lymphoma invasion of bone marrow is not subject to conditions below): hemoglobin (Hgb) ≥80g/L, neutrophil count (ANC) ≥1×10^6/L, platelet (PLT) ≥75×10^9/L. 11. Pregnancy tests for women of childbearing age shall be negative; Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year.
  • Toxicity from previous antitumor therapy ≤ grade 1 (according to CTCAE version 5.0) or to an acceptable level of inclusion/exclusion criteria (other toxicities such as alopecia and vitiligo considered by the investigator to pose no safety risk to the subject).
  • No obvious hereditary diseases.
  • Able to understand the requirements and matters of the trial, and willing to participate in clinical research as required.
  • Informed consent must be signed.

Who cannot join

  • Patients eligible for this study must not meet any of the following criteria:
  • During the screening period, there was central nervous system (CNS) invasion or a history of clinically significant central nervous system diseases, such as epilepsy and cerebrovascular diseases.
  • Women who are pregnant or breastfeeding, or who do not agree to use effective contraception during treatment and during the subsequent 1 year.
  • History of allogeneic hematopoietic stem cell transplantation, or organ transplantation.
  • History of other malignancies that have not been in remission.
  • Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy.
Show all 20Show fewer
  • Received radiotherapy within 3 months before enrollment.
  • Received immunotherapy drugs within 4 weeks before enrollment, such as anti-programmed death 1 (PD-1) antibody, anti-programmed death ligand 1 (PD-L1) antibody, CD19/CD3-bispecific antibody, and so on.
  • Patients who received any immunocellular therapy within 6 months before enrollment.
  • Confirmed evidence showing positiveness of anti-CD19 and/or anti-CD20 scFv reactions in patient serum.
  • Patients who participated in other clinical trials within 4 weeks prior to enrollment.
  • Uncontrolled infectious diseases or other serious illnesses, including but not limited to infections [e.g., human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B (HBV) or C (HCV) infection], congestive heart failure, unstable angina, arrhythmias, or that pose an unpredictable risk in the opinion of the attending physician.
  • The presence of uncontrollable serous membrane fluid, such as massive pleural effusion or ascites.
  • A history of stroke or intracranial hemorrhage within 3 months prior to enrollment.
  • Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered.
  • History of allergies to any of the ingredients in cell products.
  • Conditions in which a known mental or physical illness interferes with cooperation with the requirements of the study or disrupts the results or interpretation of the results and, in the opinion of the therapeutic investigator, makes the patient unfit for study participation.
  • There is the situation that the researcher's judgment will interfere with the whole study participation; Situations where there is significant risk to the subject; Or interferes with the interpretation of research data.
  • Inability to understand or unwillingness to sign informed consent.
  • Researchers believe that other reasons are not suitable for clinical trials.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Biotherapeutic Department of Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100853

Other trials in China

About this study

Official title: Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients

This is an open-label, phase 1/2 study has the primary objective of decitabine-primed tandem CART 19/20 in patients with B-NHL who were confirmed as r/r B cell Non-Hodgkin's Lymphoma. A total of 19 to 33 patients are planned to be enrolled and receive decitabine-primed tandem CART 19/20 cell infusion. Phase 1 (9 to 18 cases) is dose escalation part, and phase 2 (10 to 15 cases) is expansion cohort part.

Read the detailed description

Phase 1 (dose escalation)

In phase 1, 9 to 18 subjects will be enrolled. Subjects will receive 3 doses of decitabine-primed tandem CART 19/20 cell therapy (0.5 × 10^6 cells/kg, 2 × 10^6 cells/kg, 5 × 10^6 cells/kg) from low dose to high dose according to the "3 + 3" principle:

  1. Three patients were enrolled in the lowest dose group.
  2. Subsequent patients were enrolled according to the following rules:
  3. If the incidence of dose limiting toxicity (DLT) was 0/3, 3 patients were enrolled in the next high-dose group.
  4. If the incidence of DLT was 1/3, 3 patients were enrolled at the same dose; If the incidence of DLT was 1/3 + 0/3, 3 patients were enrolled in the next high-dose group. If the incidence of DLT was 1/3 + 1/3, this dose was defined as maximum tolerated dose (MTD); If the incidence of DLT was 1/3 + 2/3 or 1/3 + 3/3, the previous dose was MTD.
  5. If the incidence of DLT was 2/3 or 3/3, the previous dose was MTD.

To ensure the safety of the subjects, the first subject in each dose group was observed for at least 28 days after the cell infusion. If no DLT occurred, the remaining two subjects could be enrolled and treated at the same dose level. The safety data of all subjects in each dose group until day 28 should be reviewed and tolerated before proceeding to the next dose group trial. No dose escalation was allowed for the same subject during the trial. If a subject drop out during the observation period due to non-DLT reasons, new subjects should be enrolled to make up for the number of subjects who drop out.

Phase 2 (expansion cohort)

In phase 2, 10 to 15 subjects will be enrolled and receive decitabine-primed tandem CART 19/20 cell infusion at dose of RP2D, which will be determined based on the MTD, occurrence of DLT, the obtained efficacy results, pharmacokinetics / pharmacodynamics and other data according to the phase 1.

[Objectives]

The primary objectives of the phase 1 were to evaluate the tolerability, safety, and determine recommended phase 2 dose (RP2D). The primary purpose of the phase 2 study was to evaluate the efficacy.

Being tested
Decitabine-primed Tandem CAR19/20 engineered T cells, Fludarabine, Cyclophosphamide
Medical subject headings
Recurrence, Lymphoma, B-Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Decitabine-primed Tandem CAR19/20 engineered T cellsBiological

    Phase I dose escalation (3+3) : dose 1 (0.5 × 10^6 cells per kg) dose 2 (2 × 10^6 cells per kg) dose 3 (5 × 10^6 cells per kg)

    Phase II: Appropriate dose

  • FludarabineDrug

    Also called Fludarabine Phosphate for Injection

    Intravenous fludarabine 25-30 mg/m^2/day on days -5, -4, and -3.

  • CyclophosphamideDrug

    Also called Cyclophosphamide for Injection

    Intravenous cyclophosphamide 300-500 mg/m^2/day on days -5, -4, and -3.

Study groups in NCT04697940
Study groupRoleWhat they receive
Refractory or Relapsed Non-Hodgkin's LymphomaExperimentalA conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, autologous decitabine-primed Tandem CAR19/20 engineered T cells. Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control.
Receives: Biological: Decitabine-primed Tandem CAR19/20 engineered T cells; Drug: Fludarabine; Drug: Cyclophosphamide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phase 1: Incidence of Adverse Events (AEs)

    AE is defined as any adverse medical event from the date of randomization to 12 months after CAR T cells infusion. Among them, CRS and ICANS were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0.

    Measured: 12 months

  2. Phase 1: Incidence of Dose-Limiting Toxicities (DLTs)

    DLT was defined as CAR T cells-related events with onset within first 28 days following infusion: The development of Grade (G) 3 or higher grade CRS lasting > 2 weeks; Any CAR T cells-related AE requiring intubation; All G4 non-hematologic toxicities.

    Measured: First infusion date of CAR T cells up to 28 days

  3. Phase 1: Maximum tolerated dose (MTD)

    MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.

    Measured: 12 months

  4. Phase 1: Recommended phase 2 dose (RP2D)

    The recommended dose for phase 2 was determined through phase 1 study.

    Measured: 12 months

  5. Phase 2: Best Response Rate

    The incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as the best response to treatment assessed by investigators and based on the Lugano 2014 assessment criterion.

    Measured: 12 months

Secondary outcomes (7)

  1. Phase 2: Overall Survival (OS)

    OS is defined as the time from CAR T cells infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.

    Measured: 24 months

  2. Phase 2: Progression Free Survival (PFS)

    PFS is defined as the time from the CAR T cells infusion date to the date of disease progression assessed by investigators and based on the Lugano 2014 assessment criterion, or death any cause. Participants not meeting the criteria for progression by the analysis data cutoff date were censored at their last evaluable disease assessment date.

    Measured: 24 months

  3. Phase 2: Time to response (TTR)

    TTR is defined as the time from CAR T infusion to first assessed CR or PR by investigators and based on the Lugano 2014 assessment criterion.

    Measured: 24 months

  4. Phase 2: Duration of Response (DOR)

    DOR is defined as the date of their first CR or PR (which is subsequently confirmed) to PD assessed by investigators and based on the Lugano 2014 assessment criterion for r/r B-cell NHL, or death regardless of cause.

    Measured: 24 months

  5. Pharmacokinetics: Number and copy number of CAR T cells (phase 1 and phase 2)

    Number and copy number of CAR T cells were assessed by number in peripheral blood. Blood samples were collected before and one year after cell infusion (until CAR T cells were not detected for two consecutive times) to detect the number and copy number of CAR T cells, and to evaluate the pharmacokinetics of CAR T.

    Measured: 12 months

  6. Pharmacokinetics: Persistence of CAR T (phase 1 and phase 2)

    Persistence of CAR T cell assessed by number in peripheral blood.

    Measured: 12 months

  7. Pharmacodynamics: Peak level of cytokines in serum (phase 1 and phase 2)

    The cytokines mainly include interleukin-2 (IL-2 ), IL-6, IL-8, IL-10, tumor necrosis factor-α (TNF-α), C reactive protein (CRP), ferritin. Peak was defined as the maximum post-baseline level of the cytokine.

    Measured: Up to 28 days after infusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jan 2021
  2. Study start15 Apr 2021
  3. Primary completion31 May 2025
  4. Study completion1 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
33 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04697940
Sponsor's protocol ID
CHN-PLAGH-BT-058
Status last verified
Sep 2025
First submitted
20 Dec 2020
Last updated
19 Sep 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Decitabine-primed Tandem CAR19/20 engineered T cells, Fludarabine and Cyclophosphamide in people with Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma and Decitabine-primed Tandem CD19/CD20 CAR T Cells, run by Han weidong at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 35 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 19 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phase 1: Incidence of Adverse Events (AEs) (time frame: 12 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04697940.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in